The presentations in this multidisciplinary symposium will represent wide and yet comprehensive approaches toward the knowledge of the origin, homeostasis, differentiation, hormonal regulation and bioengineering of temporomandibular joint cells. Related StoriesNYSCF, CBR collaborate to customize creation of high-quality stem cell linesNYSCF conference to focus on translational stem cell and neuroscience researchResearchers find that stem cell treatment may reduce cognitive impairment related to dementia with Lewy bodiesTMJ disorders are a poorly understood cluster of illnesses, ranging from neuromuscular pain to severe types of arthritis. Recently, stem/progenitor cells have already been identified in TMJ disc and condyle, with potential origin from neural crest cells in advancement.Definitions of each prespecified outcome and ways of ascertainment are detailed in Section 8 in Supplementary Appendix 1. Study Oversight Fenofibrate and matching placebo were donated by Abbott Laboratories; simvastatin was donated by Merck. The drug manufacturers had no part in the design of the scholarly research, in the accrual or analysis of the info, or in the planning of the manuscript. All authors vouch for the precision and completeness of the reported data. Statistical Analysis The study was designed to recruit 5800 patients, with a power of 87 percent to detect a 20 percent decrease in the rate of the principal outcome for patients in the fenofibrate group, in comparison with placebo, assuming a two-sided alpha level of 0.05, a primary outcome rate of 2.4 percent each year in the placebo group, and an average follow-up of around 5.6 years for patients who did not have a meeting.